Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro) are no longer a niche therapy—they’re mainstream. These drugs, originally developed for diabetes and obesity management, have exploded in popularity for weight loss and metabolic change, with prescriptions and consumer interest doubling in recent years. For medspa owners, the “GLP-1 effect” is showing up everywhere: in consult conversations, treatment planning, staffing needs, and revenue predictability.
The practices that are winning aren’t hesitating, they’re building systems around it.
GLP-1 Growth Is Real and It’s Driving Aesthetic Demand
GLP-1 receptor agonists have become one of the fastest-growing classes of medications globally, with annual prescription growth averaging ~38% between 2022 and 2024, and sales projected to reach $100 billion by 2030.
As a result, medspas report a consistent increase in patient interest for post-weight-loss aesthetic services, from facial volume restoration to body tightening.
Why Aesthetic Needs Change After GLP-1 Use
GLP-1 medications don’t just reduce fat, they often produce rapid body change. That’s fantastic for overall health, but it also creates strong demand for aesthetic follow-up services:
Facial volume loss and changes in facial structure are common as patients shed weight quickly.
Skin laxity on the body can become more noticeable as fat reduction outpaces collagen remodeling.
Patient goals shift from “lose weight” to “look balanced and refreshed.”
Reports state that GLP-1 adoption is already boosting demand for medical aesthetics, particularly in practices that help patients complete their transformation.
The Key Challenge: Consultation and Conversion
The biggest missed opportunity for medspas isn’t demand—it’s conversion.
Many practices still rely on casual, unstructured consults that don’t reflect the complexity of today’s GLP-1 patient. As a result:
Patients leave without a clear plan.
Revenue per patient stays flat.
Providers miss the opportunity to build trust and long-term relationships.
Turning GLP-1 interest into a high-value aesthetic plan requires structured systems, confident communication, and a patient-journey mindset—from education to long-term outcomes.
What the Data Means for Your Practice
The GLP-1 effect is not a fad—it’s a structural change in how people approach their bodies and aesthetic goals. With rapid adoption rates, ongoing innovations (including oral GLP-1 options now entering the market), and sustained consumer interest, the downstream impact on medical aesthetics will continue through 2026 and beyond.
For medspa owners, this means:
📌 Higher-value patients who stay engaged longer
📌 More male clients who might have never considered aesthetics before
📌 Aesthetic demand that includes both face and body
📌 A need for structured, consult-driven growth systems
Those who adapt, with education, systems, and strategies offered by DAC, will be the practices that thrive in the next decade of aesthetic medicine.
